A combined regimen of subcutaneous XXXX and oral Madopar HBS in @entity191 .

@entity1 @entity191 @entity6372 @entity30303 @entity3519 @entity551
At the first stage of a pilot study involving 14 parkinsonians with motor @entity6372 , treatment with standard Madopar was substituted by a sustained-release form, Madopar HBS, which attenuated @entity6372 in @entity1 with end-of-dose impairment, but achieved only moderate improvement in @entity1 with on-off phenomena. In a second phase of the trial, 4 parkinsonians exhibiting the most severe @entity6372 of mobility and the poorest response to Madopar HBS (Hydrodynamically Balanced System) were selected for treatment with a combined regimen utilizing subcutaneous @entity30303 infusions as the additional component. The sequence of the trial was as follows: 1. standard Madopar, 2. Madopar HBS, 3. standard Madopar combined with @entity30303 infusions and 4. Madopar HBS combined with @entity30303 infusions. Steady improvement was observed along the lines of this schedule, but the best results were obtained when Madopar HBS was combined with @entity30303 infusions. Subsequently motor @entity6372 were less marked or disappeared, early-morning @entity191 decreased and @entity3519 was not recorded any longer. Even better results could be accomplished in an extended trial attempting to establish the best dosage ratio of the combination, possibly admitting increased dosage. The tolerance of the combined regimen was excellent, except in one @entity1 who transiently exhibited delusions and @entity551 . The combination of sustained-release Madopar and continuous infusions of the dopaminergic agonist @entity30303 seems to prove a more physiological and effective regimen for the treatment of severe motor @entity6372 .
